N-acetylcysteine effect on serum creatinine and cystatin C level in CKD patients

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 6, 2008, Pages 1610-1614

  Rehman, Tariq ^a   Fought, Jason ^b   Solomon, Richard ^a,c  

^a UNIVERSITY OF VERMONT   (United States)

^b St David's Georgetown Hospital   (United States)

^c FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BIOLOGICAL MARKER; CONTRAST MEDIUM; CREATININE; CST3 PROTEIN, HUMAN; CYSTATIN C; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RADIOGRAPHY; TIME;

ACETYLCYSTEINE; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CONTRAST MEDIA; CREATININE; CYSTATIN C; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 58149333516     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01560408     Document Type: Article

References (24)

1. Hoffmann U, Fischereder M, Kruger B, Drobnick W, Kramer BK: The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15: 407-410, 2004
2. Izzedine H, Guerin V, Launay-Vacher V, Bernad M, Deray G: Effect of N-acetylcysteine on serum creatinine level. Nephrol Dial Transplant 16: 1514-1515, 2001
3. Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40: 221-225, 2002
4. Hasse M, Hasse-Fielitz A, Ratnaike S, Reade MC, Bagshaw SM, Morgera S, Dragun D, Bellomo R: N-acetylcysteine does not artifactually lower plasma creatinine concentration. Nephrol Dial Transplant 23: 1581-1587, 2008
5. Mainra R, Gallo K, Moist L: Effect of N-acetylcysteine on renal function in patients with chronic kidney disease. Nephrology 12: 510-513, 2007
6. Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgartern J, Morrow JD, Stein MC, Golik A: The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 64: 2182-2187, 2003
7. Sheffner A: The mucolytic action of acetylcysteine. Tuberculol Thorac Dis 23: 31-33, 1966
8. Tepel M, Van Der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W: Prevention of radiographic-contrastagent- induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180-184, 2000
9. Gonzales D, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL: A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 5: 32-45, 2007
10. Briguori C, Columbo A, Violante A, Balestrieri P, Golia B, Scarpato P, Elia P, Lepore S, Ricciardelli B: Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25: 206-211, 2004
11. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli A: N-Acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354: 2773-2782, 2006
12. Olsson B, Johansson M, Gabrielsson J, Bolme P: Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34: 77-82, 1988
13. Moldeus P, Cotgreave IA: N-acetylcysteine. Methods Enzymol 234: 482-492, 1994
14. Borgstrom L, Kagedal B, Paulsen O: Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31: 217-222, 1986
15. Sjodin K, Nilsson E, Hallberg A, Tunek A: Metabolism of N-acety-L-cysteine: some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol 38: 3981-3985, 1989
16. Cotgrease I, Moldeus P, Schuppe I: The metabolism of N-acetylcysteine by human endothelial cell. Biochem Pharmacol 42: 13-16, 1991
17. Hussain A, Day A, Pilkey R, Yeates KE: N-acetylcysteine (NAC) does not acutely alter serum creatinine levels in patients with chronic kidney disease prior to coronary angiography [Abstract]. J Am Soc Nephrol 15: 348A, 2004
18. Genet S, Kale RK, Baquer NA: Effects of free radicals on cytosolic creatine kinase activities and protection by antioxidant enzymes and sulfhydryl compounds. Mol Cell Biochem 210: 23-28, 2000
19. Wyss M, Kaddurah-Daouk R: Creatine and creatinine metabolism. Physiol Rev 3: 1108-1213, 2000
20. Bakris G, Lass N, Gaber AO, Jones JD, Burnett JC Jr: Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 258: F115-F120, 1990
21. Abrahamson M, Olafason I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A: Structure and expression of the human cystatin C gene. Biochem J 268: 287-294, 1990
22. Tenstad O, Roald AB, Grubb A, Aukland K: Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 56: 409-414, 1996
23. Hatano M: Clinical study of tubular creatinine secretion in renal dysfunction. Nippon Jinzo Gakkai Shi 11: 1097-1104, 1991
24. Herrera J, Rodriquez-Iturbe B: Stimulation of tubular secretion of creatinine in health and in conditions associated with reduced nephron mass: evidence for tubular functional reserve. Nephrol Dial Transplant 3: 623-629, 1998